Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess Efficacy and Safety of Two Regimens of Crisaborole Ointment 2% in Japanese Participants Aged ≥2 Years With Mild to Moderate Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female participants ages; Cohort 1: 12 years and older at the time of consent. Cohort 2: 2 years to under 12 years old at the time of consent.~* Has confrimed clinical diagnosis of active AD according to Hanifin and Rajka criteria and has at least 6 months history prior to screening and has been clinically stable for more than 1 month~* Has at least 1% and no more than 30% BSA at baseline/Day1, excluding scalp, genitals and groin area~* Has a Investigator's static global assessment (ISGA) score of Mild (2) or Moderate (3) on Day 1.~Exclusion Criteria:~* Has other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.~* Participants had previous treatment with any topical or systemic PDE-4 inhibitor.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Crisaborole ointment 2% once daily (QD) vs vehicle QD (Type: EXPERIMENTAL): intra-participant comparison, treatment will be randomly assigned to target lesion 1 and lesion 2.
- Crisaborole ointment 2% twice daily (BID) vs vehicle BID (Type: EXPERIMENTAL): Intra-participant comparison, treatment will be randomly assigned to target lesion 1 and lesion 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).